First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.

Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ (2014) 1.25

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis (2013) 1.17

Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Oncotarget (2014) 1.02

Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Int J Cancer (2014) 1.01

Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. Oncotarget (2014) 0.96

LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther (2012) 0.92

Moringa Oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells. BMC Complement Altern Med (2013) 0.86

A potent lead induces apoptosis in pancreatic cancer cells. PLoS One (2012) 0.85

Cutaneous metastases secondary to pancreatic cancer. World J Gastrointest Oncol (2012) 0.82

Pilot study evaluating broccoli sprouts in advanced pancreatic cancer (POUDER trial) - study protocol for a randomized controlled trial. Trials (2014) 0.82

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Res Treat (2014) 0.81

Spiclomazine induces apoptosis associated with the suppression of cell viability, migration and invasion in pancreatic carcinoma cells. PLoS One (2013) 0.80

Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. PLoS One (2016) 0.77

Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells. Oncotarget (2016) 0.77

Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. Clin Exp Med (2016) 0.76

EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. Biomacromolecules (2015) 0.75

Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39

Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57

Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55

Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44

Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43

Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30

Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29

Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18

Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17

Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07

Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06

Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 1.06

Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04

Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03

Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02

Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02

Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02

Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02

Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00

Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00

Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99

Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98

Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96

IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96

Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96

Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95

Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP (2008) 0.94

Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.94

Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93

Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93

FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91

Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90

Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89

Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89

Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89

Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89

Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89

First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.88

Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88

Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87

Early detection of pancreatic cancer. JOP (2012) 0.87

Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87

Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87

Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87

Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87

Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.86

Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86

Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.86

Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86

Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86

Quality of life in patients with pancreatic cancer. JOP (2012) 0.86

Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.86

Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85

Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85

Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85

Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85

Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.85

Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84

Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.84

Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.84

Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84

Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84

Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.84

Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84

Advancements in the management of pancreatic cancer. JOP (2009) 0.83

Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83

PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83

First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83

Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.83

Diabetes and pancreatic cancer. JOP (2014) 0.83

Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83

Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83

Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82

Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol (2012) 0.82

Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP (2009) 0.82

Role of anticoagulation in the management of pancreatic cancer. JOP (2009) 0.82

Biomarkers in neuroendocrine tumors. JOP (2013) 0.82

The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82

Locally advanced pancreatic adenocarcinoma: update and progress. JOP (2012) 0.82

Metastatic pancreatic cancer: the dilemma of quality vs. quantity of life. JOP (2013) 0.81

Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer (2009) 0.81

Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). JOP (2015) 0.81

Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.81

EUS-guided pancreatic diagnosis and beyond. Highlights from the "2011 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.81

Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma. JOP (2010) 0.81

Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? JOP (2008) 0.81

Elderly patients with pancreatic cancer. JOP (2014) 0.81

Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. JOP (2014) 0.81

Novel treatment approaches for locally advanced pancreatic cancer. JOP (2014) 0.81

KRAS in pancreatic cancer. JOP (2014) 0.81

Adjuvant therapy of pancreatic cancer. JOP (2013) 0.80

Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? JOP (2007) 0.80

Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.80

Screening and detection of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.80

Risk determination for pancreatic cancer. JOP (2014) 0.80